Johny Marice
A groundbreaking clinical trial has illuminated a potential new avenue for addressing the pervasive issue of shift work disorder, particularly among the often-overlooked population of early morning shift workers. Researchers at Mass General Brigham have demonstrated that the wake-promoting medication solriamfetol (Sunosi) significantly improved alertness and cognitive performance in individuals whose workdays begin between 3 a.m. and 7 a.m. This marks the first clinical trial to specifically investigate a treatment for shift work disorder in this demographic, addressing a critical gap in understanding and therapeutic intervention. The findings, published in the esteemed New England Journal of Medicine (NEJM) Evidence, offer a beacon of hope for millions who grapple with the persistent fatigue and associated risks of working outside conventional hours.
The Overlooked Burden of Early Shifts
While overnight shifts often capture public attention regarding the disruptive nature of non-standard work schedules, the reality is that a substantial portion of the workforce operates on an early morning schedule. An estimated one in four workers globally do not adhere to a typical 9-to-5 workday, with many commencing their duties long before sunrise. These individuals, often accustomed to early rising, may not even self-identify as "shift workers," viewing their routine as simply an earlier start to the day. However, this biological misalignment can still trigger the debilitating effects of shift work disorder, characterized by disrupted sleep patterns, chronic daytime sleepiness, and a cascade of negative health and performance outcomes.
Dr. Charles A. Czeisler, the senior author of the study and Chief and Senior Physician of the Division of Sleep and Circadian Medicine at Mass General Brigham, underscored the significance of this research. "Until now, no clinical trial had tested a treatment for shift work disorder in early-morning shift workers, even though this is the most common type of shift schedule," Dr. Czeisler stated. "This study addresses a major gap by focusing on the workers who start their day when most people are still asleep." He emphasized that these early risers are actively fighting their body’s natural inclination to sleep during these critical hours.
Understanding the Biological Clock Disruption
The human body operates on an intricate internal clock, the circadian rhythm, which dictates cycles of sleep and wakefulness. This rhythm is primarily influenced by light exposure. For individuals working early morning shifts, their wake-up times often fall within a period when the brain is biologically programmed for sleep. This inherent conflict makes maintaining alertness exceptionally challenging, regardless of an individual’s motivation.
Dr. Kirsi-Marja Zitting, the lead author and an investigator with the Division of Sleep and Circadian Medicine at Mass General Brigham, elaborated on this biological imperative. "People who start work between 3 a.m. and 7 a.m. are waking up at a time when the brain is biologically programmed to sleep. That makes staying alert extraordinarily difficult, even when they are highly motivated," Dr. Zitting explained. She further highlighted the "double burden" faced by these workers: persistent sleepiness during their work hours and significant difficulty achieving adequate restorative sleep when they have the opportunity. This cycle of insufficient sleep and forced wakefulness can have profound and far-reaching consequences.
The Pervasive Health and Safety Risks
The implications of shift work disorder extend far beyond mere tiredness. Chronic sleep deprivation and disrupted circadian rhythms are linked to a spectrum of serious health concerns, including cognitive impairment, reduced mental acuity, and diminished productivity. Safety is also a major casualty, with increased risks of motor vehicle accidents and workplace injuries. Studies have shown that shift workers are disproportionately represented in accidents, underscoring the critical need for effective interventions.
Existing pharmacological interventions, such as modafinil, have been used to promote wakefulness. However, these medications have primarily been studied in the context of overnight shift work and can sometimes interfere with natural sleep patterns later in the day, potentially exacerbating the problem. This limitation underscores the need for treatments that are both effective and conducive to healthy sleep hygiene.
Solriamfetol: A Novel Approach to Alertness
Solriamfetol, the drug investigated in this pivotal trial, represents a promising therapeutic option. It is already approved for the treatment of excessive daytime sleepiness in individuals with obstructive sleep apnea and narcolepsy. Its mechanism of action, which promotes wakefulness by enhancing dopamine and norepinephrine activity, is thought to provide sustained alertness without significantly disrupting later sleep cycles. This characteristic makes it particularly appealing for early morning shift workers who require sustained wakefulness during their work hours and then need to transition to sleep during the day.
Clinical Trial Design and Key Findings
The clinical trial enrolled 78 participants who had been diagnosed with shift work disorder and were employed in early morning shifts. The study employed a rigorous randomized, placebo-controlled design. Participants were assigned to receive either solriamfetol or a placebo on their workdays for a duration of four weeks.
To objectively assess the drug’s efficacy, researchers conducted controlled sleep-wake assessments in a low-stimulation environment during hours that mirrored the participants’ typical work schedules. This simulated work setting allowed for precise measurement of the participants’ ability to remain awake and alert. In addition to these objective measures, participants also provided subjective reports on their daily functioning, and regular clinical assessments were conducted.
The results were compelling. Participants who received solriamfetol demonstrated statistically significant improvements in their ability to stay awake. They reported feeling less sleepy and exhibited a greater capacity to remain alert during the simulated work hours compared to the placebo group. Furthermore, both the participants themselves and their treating clinicians observed improvements in overall daily functioning, enhanced work performance, and a greater ability to manage their responsibilities.
Dr. Czeisler highlighted the clinical significance of these findings: "The improvement we saw is clinically meaningful. These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life," he stated. "Shift workers are essential to how our society functions, yet they often pay a hidden biological cost. This study shows we can do better for them."
Implications for Public Health and Safety
The implications of this research are substantial. By providing a targeted and effective treatment for early morning shift workers, solriamfetol has the potential to mitigate the negative health and safety consequences associated with shift work disorder. Improved alertness can lead to fewer errors, reduced risk of accidents, and enhanced overall job performance. This, in turn, can contribute to a safer and more productive workforce, benefiting not only the individuals but also their employers and society at large.
The economic impact of shift work disorder is also considerable, encompassing lost productivity, increased healthcare costs, and the potential for costly accidents. By addressing the underlying cause of excessive sleepiness, interventions like solriamfetol could lead to significant economic savings.
Future Directions and Broader Research
Despite the promising results, the researchers acknowledge that further investigation is warranted. The current study, while robust, had a relatively short duration of four weeks and focused on otherwise healthy adults. Long-term efficacy and safety data are crucial for comprehensive understanding and widespread clinical adoption.
The Mass General Brigham team is already embarking on the next phase of research. They are currently enrolling participants for a follow-up clinical trial designed to evaluate solriamfetol in overnight shift workers. This expanded research aims to provide a more complete picture of the drug’s effectiveness across different shift schedules and potentially support broader regulatory approval for the treatment of shift work disorder in its entirety.
The study authors, including Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, and Jeanne F. Duffy from Mass General Brigham, along with Eileen B. Leary, represent a significant collaborative effort in sleep and circadian medicine. The research was funded by Jazz Pharmaceuticals, Axsome Therapeutics, and the Brigham and Women’s Hospital Center for Clinical Investigation, and its progress is tracked under clinical trial identifier NCT04788953.
A Call for Greater Recognition and Support
This research serves as a crucial reminder of the profound impact that non-standard work schedules have on the health and well-being of a significant segment of the population. Early morning shift workers, often operating in essential roles, deserve greater recognition and support for the biological challenges they face. The development and validation of effective treatments like solriamfetol represent a vital step forward in ensuring that these individuals can perform their duties safely and maintain a higher quality of life, both on and off the job. The ongoing research promises to further illuminate the path towards comprehensive solutions for the complex issue of shift work disorder.
